Margarida Corte-Real

Ms. Margarida Corte-Real

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Cosmetics
Verified
Journal Article
Open access
PDF file
Ana Margarida Alves-CruzAna Margarida Alves-Cruz
Ana Margarida Alves-Cruz
MCMargarida Corte-Real
Margarida Corte-Real
MMMatilde Marques
Matilde Marques
Francisco VeigaFrancisco Veiga
Francisco Veiga
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
PPPatrícia C. Pires
Patrícia C. Pires
The skin is the human body’s largest organ and serves as a crucial boundary between the body and the external environment. As a natural process, skin aging cannot be avoided, and it causes changes in the skin’s strength, structure, elasticity, and integrity. Many approaches have been developed over the years to study the skin, including in vivo and in vitro methods. Nevertheless, animal assays have ethical issues and a lack of reproducibility. Hence, in vitro skin models have been increasingly developed and used. For the assessment of the potential of the anti-aging activity of compounds of different origins, the most commonly used in vitro assays are the ones evaluating antioxidant, anti-collagenase, anti-elastase, anti-hyaluronidase, anti-tyrosinase, anti-inflammatory, antiglycation, or moisturizing activity, and the induction of skin cell proliferation/anti-senescence effects or the inhibition of matrix metalloproteinase production. The purpose of this review is to summarize the most commonly used in vitro models for the evaluation of skin aging and cometic products’ anti-aging efficacy, providing a useful guide for researchers in the field. Overall, these assays provide important data on the safety and efficacy of anti-aging compounds, and a foundation for research on and the eventual introduction of formulations into the cosmetics market.

12 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MCMargarida Corte-Real
Margarida Corte-Real
Francisco VeigaFrancisco Veiga
Francisco Veiga
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
PPPatrícia C. Pires
Patrícia C. Pires
Skin cancer is a high-incidence complex disease, representing a significant challenge to public health, with conventional treatments often having limited efficacy and severe side effects. Nanocarrier-based systems provide a controlled, targeted, and efficacious methodology for the delivery of therapeutic molecules, leading to enhanced therapeutic efficacy, the protection of active molecules from degradation, and reduced adverse effects. These features are even more relevant in dual-loaded nanosystems, with the encapsulated drug molecules leading to synergistic antitumor effects. This review examines the potential of improving the treatment of skin cancer through dual-loaded liposomal systems. The performed analysis focused on the characterization of the developed liposomal formulations’ particle size, polydispersity index, zeta potential, encapsulation efficiency, drug release, and in vitro and/or in vivo therapeutic efficacy and safety. The combination of therapeutic agents such as doxorubicin, 5-fluorouracil, paclitaxel, cetuximab, celecoxib, curcumin, resveratrol, quercetin, bufalin, hispolon, ceramide, DNA, STAT3 siRNA, Bcl-xl siRNA, Aurora-A inhibitor XY-4, 1-Methyl-tryptophan, and cytosine–phosphate–guanosine anionic peptide led to increased and targeted anticancer effects, having relevant complementary effects as well, including antioxidant, anti-inflammatory, and immunomodulatory activities, all relevant in skin cancer pathophysiology. The substantial potential of co-loaded liposomal systems as highly promising for advancing skin cancer treatment is demonstrated.